Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1358894 in Healthy Males
NCT03210272Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of bi 1358894 in major depressive disorder (MDD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Subjects With Drug- Related Adverse Event up to 33 days. Started Jul 2017; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03210272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03210272.